KEYTRUDA® Granted Favorable EU CHMP Opinion for NSCLC Treatment
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines…
AbbVie and Tentarix Partner to Innovate Conditional Multi-Specific Biologics for Oncology and Immunology
AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics have unveiled a significant collaboration aimed at pioneering the development of conditionally-active, multi-specific biologics targeting oncology and immunology. This strategic alliance will harness…
BOTOX® Cosmetic (onabotulinumtoxinA) Unveils 2024 Grant Initiative to Empower Female Entrepreneurs
Today, Allergan Aesthetics, a subsidiary of AbbVie (NYSE: ABBV), has officially launched the application process for its 2024 BOTOX® Cosmetic grant program, aimed at supporting women entrepreneurs. Following a successful…
Understanding Heart Failure: It’s Likely Not What You Imagine
Carlos Mercado experienced a sudden onset of symptoms reminiscent of a heart attack while settling down for an evening of television in 2022. The racing heart, chest pain, and cold…
KalVista Pharmaceuticals Awarded UK Innovation Passport for Sebetralstat
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical-stage pharmaceutical company specializing in the discovery, development, and commercialization of oral, small molecule protease inhibitors, has announced today that the UK Medicines and…
Argenx’s VYVGART Hytrulo Receives FDA Priority Review for Chronic Inflammatory Demyelinating Polyneuropathy
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company dedicated to enhancing the well-being of individuals with severe autoimmune conditions, has announced today that the U.S. Food and Drug…
Diakonos Oncology Appoints Veteran BioPharma Senior Executive, Dr. Paul Lammers, to Board of Directors
Diakonos Oncology Corp. (“Diakonos”), a company in the clinical stage of immuno-oncology, has announced today the appointment of Dr. Paul Lammers, M.D., M.Sc., a distinguished executive with over 35 years…
Health Canada Grants Approval for Remsima™ SC in Treating Inflammatory Bowel Disease (IBD)
Celltrion Healthcare Canada Limited has announced today that Health Canada has granted approval for Remsima™ SC as maintenance therapy for adults with moderately to severely active ulcerative colitis (UC) and…
MRM Health Initiates Clinical Research in Parkinson’s Disease
MRM Health, a clinical-stage biopharmaceutical firm, has obtained regulatory and ethics committee approval to commence an observational, cross-sectional clinical trial examining the role of the small intestinal microbiome in Parkinson’s…
AbbVie Reveals Latest Gastroenterology Data at ECCO Congress
AbbVie has revealed that 17 AbbVie-sponsored abstracts, featuring fresh insights from its inflammatory bowel disease (IBD) portfolio, have been accepted for showcase at the 19th Congress of European Crohn’s and…
Lupin Granted U.S. FDA Approval for Minzoya (Levonorgestrel and Ethinyl Estradiol Tablets, USP, and Ferrous Bisglycinate Tablets)
Leading global pharmaceutical company Lupin Limited (Lupin) has announced its receipt of approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for…
EffRx Pharmaceuticals Enters Exclusive Licensing and Distribution Partnership with Lupin for BINOSTO® Commercialization in Vietnam & Philippines
EffRx Pharmaceuticals SA, a pharmaceutical company specializing in musculoskeletal and rare diseases medications, has disclosed the signing of an exclusive licensing and distribution arrangement for Binosto® in Vietnam and the…